Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | WNT1 | P04628 | 9/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | CLK3 | P49761 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20949263 | 0.90 | DYRK1A (0.81) | DYRK1AGSK3BWNT1ABL1CLK2 | |
| SCHEMBL20946625 | 0.90 | DYRK1A (0.81) | DYRK1AGSK3BWNT1ABL1CLK2 | |
| SCHEMBL20945965 | 0.87 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20947631 | 0.87 | DYRK1A (0.77) | DYRK1AGSK3BWNT1ABL1CLK2 | |
| SCHEMBL20949828 | 0.86 | DYRK1A (0.76) | DYRK1AGSK3BWNT1ABL1CLK2 | |
| SCHEMBL20949478 | 0.86 | DYRK1A (0.75) | DYRK1AGSK3BWNT1ABL1CLK2 | |
| SCHEMBL19540265 | 0.84 | DYRK1A (0.73) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540158 | 0.83 | DYRK1A (0.72) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL30004066 | 0.83 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19516597 | 0.83 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062240-A1 | METHODS OF TREATING CANCER USING A CLK INHIBITOR | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-03 | — | — | US | disclosed |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK2, DYRK3 | DYRK1A 1/4885GSK3B 11/4885WNT1 8/4885 |
| US-20220062240-A1 | METHODS OF TREATING CANCER USING A CLK INHIBITOR | CLK2, CLK1, CLK3 | DYRK1A 1172/4885GSK3B 1277/4885WNT1 3129/4885 |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK2 | DYRK1A 1/4885GSK3B 12/4885WNT1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.